Heron Therapeutics Inc. (HRTX)

19.20
0.06 0.31
NASDAQ : Health Technology
Prev Close 19.14
Open 19.08
Day Low/High 18.88 / 19.35
52 Wk Low/High 16.20 / 41.55
Volume 621.95K
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 79.19M
Market Cap 1.52B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Heron Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - HRTX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Heron Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - HRTX

NEW YORK, June 17, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Heron Therapeutics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Heron Therapeutics, Inc.

Heron Therapeutics To Present At 2019 JMP Securities Life Sciences Conference

Heron Therapeutics To Present At 2019 JMP Securities Life Sciences Conference

SAN DIEGO, June 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet...

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

NEW YORK, June 12, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc.

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP ("GPM"), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Heron Therapeutics, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors (HRTX)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors (HRTX)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Heron Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood announces that on June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc.

HRTX Class Action Alert: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. -- HRTX

HRTX Class Action Alert: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. -- HRTX

NEW YORK, June 4, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Heron...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc.

First Week Of July 19th Options Trading For Heron Therapeutics (HRTX)

First Week Of July 19th Options Trading For Heron Therapeutics (HRTX)

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Heron Therapeutics To Present At Jefferies 2019 Healthcare Conference

Heron Therapeutics To Present At Jefferies 2019 Healthcare Conference

SAN DIEGO, May 29, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...

HRTX: Insiders Vs. Shorts

HRTX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Heron Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 16.55 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Heron Therapeutics Announces Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy

Heron Therapeutics Announces Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy

SAN DIEGO, May 21, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...

Lifshitz & Miller LLP Announces Investigation Of 3M Company, Aquantia Corporation, Chesapeake Lodging Trust, Fluor Corporation, Gardner Denver Holdings, Inc., Heron Therapeutics, Inc., Intermolecular, Inc. And Mellanox Technologies, Ltd.

Lifshitz & Miller LLP Announces Investigation Of 3M Company, Aquantia Corporation, Chesapeake Lodging Trust, Fluor Corporation, Gardner Denver Holdings, Inc., Heron Therapeutics, Inc., Intermolecular, Inc. And Mellanox Technologies, Ltd.

NEW YORK, May 13, 2019 /PRNewswire/ --  3M Company (MMM) Lifshitz & Miller announces investigation into possible securities laws violations in connection with 3M's reported financial and operating results for the first quarter of 2019.

Heron Therapeutics Announces Financial Results For The Three Months Ended March 31, 2019 And Highlights Recent Corporate Progress

Heron Therapeutics Announces Financial Results For The Three Months Ended March 31, 2019 And Highlights Recent Corporate Progress

SAN DIEGO, May 9, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...

Heron Therapeutics To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

Heron Therapeutics To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

SAN DIEGO, May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...

Heron Therapeutics Partners With The National Academy Of Medicine To Counter The Opioid Epidemic In The United States

Heron Therapeutics Partners With The National Academy Of Medicine To Counter The Opioid Epidemic In The United States

SAN DIEGO, May 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient...

Dealing With Biotech Stocks That Face Setbacks

Dealing With Biotech Stocks That Face Setbacks

Knowing when to continue to fish or cut bait is something that develops over time in this space.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Heron Therapeutics, Inc. - HRTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Heron Therapeutics, Inc. - HRTX

NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Heron Therapeutics, Inc.

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

- Complete Response Letter Requests Additional Chemistry Manufacturing and Controls (CMC) and Non-Clinical Information -

First Week Of HRTX December 20th Options Trading

First Week Of HRTX December 20th Options Trading

Investors in Heron Therapeutics Inc saw new options become available this week, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

These 3 Biotech Stocks Are Moving Closer to Profitability

These 3 Biotech Stocks Are Moving Closer to Profitability

Here are updates on small biotech/biopharma names I have profiled before.

3 Promising Small Biotech Stocks to Watch

3 Promising Small Biotech Stocks to Watch

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Heron Announces European Medicines Agency Validation Of Marketing Authorisation Application For HTX-011 For Postoperative Pain Management

Heron Announces European Medicines Agency Validation Of Marketing Authorisation Application For HTX-011 For Postoperative Pain Management

SAN DIEGO, April 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet...

First Week Of HRTX April 18th Options Trading

First Week Of HRTX April 18th Options Trading

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the April 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options chain for the new April 18th contracts and identified one put and one call contract of particular interest.